
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. is projecting a robust fourth-quarter net revenue between $115 million and $135 million, with an increase in full-year 2025 pro forma net revenue guidance raised to $390 million to $410 million, driven by accelerated adoption of its product, DefenCath. Additionally, the company anticipates fully synergized pro forma adjusted EBITDA to reach between $220 million and $240 million, reflecting strong financial performance and operational efficiency. The positive outlook is further supported by higher-than-expected utilization rates among outpatient dialysis customers and the upcoming potential catalyst from top-line data expected in 2Q26 related to Rezzayo.
Bears say
Cormedix Inc is positioned to capitalize on a significant market opportunity with Niyadas, estimated between $100 million to $200 million, which could enhance its EBITDA due to high gross margins. However, the company faces notable challenges from the uncertainty surrounding the TDAPA pricing headwind, which may negatively impact revenue performance. This combination of potential market opportunity and existing pricing pressures contributes to an overall negative outlook for Cormedix's stock in the near term, despite some anticipated tailwinds in the longer term.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares